Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside
the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation
therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune
system from rejecting the donor's stem cells. The donated stem cells may replace the
patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor
effect). Sometimes the transplanted cells from a donor can also make an immune response
against the body's normal cells. Giving pentostatin before transplant and cyclosporine or
mycophenolate mofetil after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving pentostatin together with
photopheresis and total-body irradiation work before donor bone marrow transplant in treating
patients with myelodysplastic syndromes.